Crossmark

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors

Crossref DOI link: https://doi.org/10.1007/s12094-017-1702-6

Published Online: 2017-06-19

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koinis, F.

Voutsina, A.

Kalikaki, A.

Koutsopoulos, A.

Lagoudaki, E.

Tsakalaki, E.

Dermitzaki, E. K.

Kontopodis, E.

Pallis, A. G.

Georgoulias, V.

Kotsakis, A.
License Information

License valid from 2017-06-19